Ajanta Pharma Limited (AJANTPHARM) Price & Analysis

Compare

4 Followers

AJANTPHARM Stock Chart & Stats

₹2512.80

-₹25.05(-0.84%)

At close: Jan 09 4:00 PM EST

₹2512.80

-₹25.05(-0.84%)

Day’s Range― - ―

52-Week Range₹2,022.05 - ₹3,115.00

Previous CloseN/A

Volume47.67K

Average Volume (3M)2.10K

Market Cap

₹313.94B

Enterprise Value₹321.41B

Total Cash (Recent Filing)₹6.14B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)32.2

Beta0.36

Next Earnings

Feb 04, 2026

EPS Estimate

19.25

Last Dividend Ex-Date

Nov 10, 2025

Dividend Yield1.11%

Share Statistics

EPS (TTM)20.80

Shares Outstanding124,935,620

10 Day Avg. Volume2,991

30 Day Avg. Volume2,099

Financial Highlights & Ratios

PEG Ratio2.64

Price to Book (P/B)8.64

Price to Sales (P/S)7.05

P/FCF Ratio39.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹3,200.00

Price Target Upside27.35% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Ajanta Pharma Limited News

Ajanta Pharma to Consider Interim Dividend Declaration

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) has provided an update. Ajanta Pharma Limited has announced that its Board...

1M ago

Ajanta Pharma to Consider Interim Dividend for FY 2026

Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) has provided an update. Ajanta Pharma Limited has announced that its Board...

1M ago

Ajanta Pharma Reports Strong Q1 FY 2026 Financial Results

An update from Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) is now available. Ajanta Pharma Limited reported a robust...

4M ago

Ajanta Pharma to Announce Q4 FY 2025 Financial Results

An announcement from Ajanta Pharma Limited ( ($IN:AJANTPHARM) ) is now available. Ajanta Pharma Limited has announced that...

7M ago

AJANTPHARM FAQ

What was Ajanta Pharma Limited’s price range in the past 12 months?

Ajanta Pharma Limited lowest stock price was ₹2022.05 and its highest was ₹3115.00 in the past 12 months.

What is Ajanta Pharma Limited’s market cap?

Ajanta Pharma Limited’s market cap is ₹313.94B.

When is Ajanta Pharma Limited’s upcoming earnings report date?

Ajanta Pharma Limited’s upcoming earnings report date is Feb 04, 2026 which is in 70 days.

How were Ajanta Pharma Limited’s earnings last quarter?

Ajanta Pharma Limited released its earnings results on Nov 03, 2025. The company reported ₹20.8 earnings per share for the quarter, beating the consensus estimate of ₹20.538 by ₹0.262.

Is Ajanta Pharma Limited overvalued?

According to Wall Street analysts Ajanta Pharma Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ajanta Pharma Limited pay dividends?

Ajanta Pharma Limited pays a Annually dividend of ₹28 which represents an annual dividend yield of 1.11%. See more information on Ajanta Pharma Limited dividends here

What is Ajanta Pharma Limited’s EPS estimate?

Ajanta Pharma Limited’s EPS estimate is 19.25.

How many shares outstanding does Ajanta Pharma Limited have?

Ajanta Pharma Limited has 124,935,620 shares outstanding.

What happened to Ajanta Pharma Limited’s price movement after its last earnings report?

Ajanta Pharma Limited reported an EPS of ₹20.8 in its last earnings report, beating expectations of ₹20.538. Following the earnings report the stock price went up 3.05%.

Which hedge fund is a major shareholder of Ajanta Pharma Limited?

Currently, no hedge funds are holding shares in IN:AJANTPHARM

Company Description

Ajanta Pharma Limited

Ajanta Pharma Limited (AJANTPHARM) is a global pharmaceutical company headquartered in Mumbai, India, focusing on the development, manufacturing, and marketing of a wide range of pharmaceutical products. With a strong presence in both domestic and international markets, Ajanta operates primarily in the segments of branded generics, specialty pharmaceuticals, and over-the-counter medications. The company offers a diverse portfolio that includes formulations for various therapeutic areas such as cardiology, dermatology, and pain management, along with a commitment to research and development for innovative healthcare solutions.

Ajanta Pharma Limited (AJANTPHARM) Earnings & Revenues

Historic Earnings Reports

AJANTPHARM Stock 12 Month Forecast

Average Price Target

₹3,200.00

▲(27.35% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2423":"₹2,423","2812":"₹2,812","3201":"₹3,201","2617.5":"₹2,617.5","3006.5":"₹3,006.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹3.20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹3.20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹3.20K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2423,2617.5,2812,3006.5,3201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2424.87,2484.4953846153844,2544.120769230769,2603.746153846154,2663.3715384615384,2722.996923076923,2782.6223076923075,2842.2476923076924,2901.873076923077,2961.4984615384615,3021.123846153846,3080.749230769231,3140.3746153846155,{"y":3200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2424.87,2484.4953846153844,2544.120769230769,2603.746153846154,2663.3715384615384,2722.996923076923,2782.6223076923075,2842.2476923076924,2901.873076923077,2961.4984615384615,3021.123846153846,3080.749230769231,3140.3746153846155,{"y":3200,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2424.87,2484.4953846153844,2544.120769230769,2603.746153846154,2663.3715384615384,2722.996923076923,2782.6223076923075,2842.2476923076924,2901.873076923077,2961.4984615384615,3021.123846153846,3080.749230769231,3140.3746153846155,{"y":3200,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2736.34,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3136.48,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3192,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3010.45,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2994.73,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2969.36,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2668.48,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2459.92,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2586.8,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2586.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2477.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2664.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2424.87,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >